Since 2020, BLS has advised Lilly on the site selection and incentives negotiation for 10 new U.S. manufacturing and R&D sites, resulting in more than $50 billion in announced investment, 6,500 new positions and more than $2.9 billion in state and local incentives secured.
In Europe, BLS and our European partner firm, Location Decisions, have assisted Lilly with three recent manufacturing site selection requirements, resulting in more than $7.5 billion in investment and 2,000 announced jobs.
Across our relationship with Lilly, BLS has provided a full range of strategic location advisory services, including multi-state site selection, infrastructure due diligence, labor market analysis, incentives strategy & transaction management, utility & infrastructure evaluations, risk assessments, and incentives compliance support.
US Project Highlights
- Alabama (API Manufacturing)
- Indiana (API Manufacturing, Gene Therapy Manufacturing, and R&D – x2 sites)
- Massachusetts (R&D)
- North Carolina (Injectables Manufacturing – x2 sites)
- Pennsylvania (Injectables Manufacturing)
- Texas (API Manufacturing)
- Virginia (ADC Manufacturing)
- Wisconsin (Injectables Manufacturing)
Europe Project Highlights
- Germany (Injectables Manufacturing)
- Ireland (API Manufacturing)
- The Netherlands (Oral Solid Dose Manufacturing)